摘 要恶性肾横纹肌样瘤(malignant rhabdoid tumor of the kindey,MRTK)是发生在肾脏的恶性横纹肌样瘤(malignant rhabdoid tumor,MRT),好发于婴幼儿时期,因临床表现多为肉眼、血尿、腹痛等症状,常被误诊为肾母细胞瘤。恶性肾横纹肌样瘤常用的治疗方法是肿瘤切除术,并辅以放、化疗为主的综合性治疗手段,但预后效果较差,常短期内死于肿瘤的快速复发或转移,因此挖掘新的 MRTK 标记物对于 MRTK 患者的预后极为关键。近年来,高通量测序技术快速发展,产生了海量与肿瘤相关的组学数据,通过分析与挖掘这些数据,可以有效的理解癌症的分子机理。同时,从系统生物学角度发现决定癌症发生发展的分子标志物,对于提高预后预测的精确度具有重要意义。在此次研究中,我们通过分析与 MRTK 相关的组学数据,发现了 1 个呈正相关的长链非编码 RNA(long noncoding RNAs , lncRNA) : LINC00880 ; 4个 呈 负 相 关 的lncRNA :RP11_463I20.2、AC004791.2、AP000476.1、RP11_134K13.4,呈正相关的 lncRNA 在高风险组中显著表达,所以 LINC00880 基因可以作为新的 MRTK 的标记物用于临床诊断。最终,我们利用这 5 个 lncRNA 建立了用于临床决策支持系统(Clinical Decision Support System,CDSS)的风险值预测模型,该模型能够提高临床决策的准确度,为 MRTK 患者的预后提供帮助。关键词:组学数据;临床决策支持系统;生存分析PAGE \* MERGEFORMAT2AbstractMalignant rhabdoid tumor of the kindey(MRTK) is a malignant rhabdoid tumor(MRT) that occurs in the kidney and occurs in infancy. Because the clinical manifestations are mostly naked eye, hematuria, abdominal pain and other symptoms, it is often misdiagnosed as nephroblastoma.Tumor resection is MRTK commonly used treatment and is supplemented with comprehensive treatment based on radiotherapy and chemotherapy, but the prognosis is poor and often dies of rapid recurrence or metastasis of the tumor in the short term. therefore, the excavation of new MRTK markers is crucial for the prognosis of MRTK patients.In recent years, high-throughput sequencing technology has developed rapidly,...